Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study
Source : https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003874
Mie Agermose Gram, Jens Nielsen, Astrid Blicher Schelde, Katrine Finderup Nielsen, Ida Rask Moustsen-Helms, Anne Katrine Bjørkholt Sørensen, Palle Valentiner-Branth, Hanne-Dorthe Emborg Subject Areas For more information about PLOS Subject...
/>
Conclusions: In this study, we observed a large reduction in the risk of SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine, compared with unvaccinated individuals.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Source : https://www.nejm.org/doi/full/10.1056/NEJMoa2116846
Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID...
CONCLUSIONS: Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.
Conclusions and Relevance: This cohort study found that, among patients with obesity, substantial weight loss achieved with surgery was associated with improved outcomes of COVID-19 infection. The findings suggest that obesity can be a modifiable risk factor for the severity of COVID-19 infection.
Highlights
- Vaccination to prevent severe cases of COVID-19 is key to controlling the pandemic.
- Some vaccines may trigger rare autoimmune adverse events.
- AZD1222 is here reported to trigger relapses of MS and NMOSD.
Discussion: Most adolescents with MIS-C for whom vaccination was indicated in France had not been vaccinated. These results suggest that COVID-19 mRNA vaccination was associated with a lower incidence of MIS-C in adolescents. The median of 25 days between single vaccine injection and MIS-C onset compared with a mean 28-day delay between...